Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Tanabe Pharma America Inc (TPA), effective immediately.
In July, MTPC said that it would change name to Tanabe Pharma Corporation, effective 1 December 2025, following its acquisition by private investment firm Bain Capital.
TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions, the company said.
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
European Commission approves Celltrion's Remsima IV liquid formulation
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
Vascarta and CUNY report positive preclinical results in glioblastoma treatment